A recent study suggested that combination of 5′-AZA associated with FLT3 inhibitor leads to a high antileukemic activity, which represents a novel approach to target FLT3/ITD mutated AML patients [28]. This evidence concerns the gene FLT3 and acute myeloid leukemia.